Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127 EUR | -1.17% | -3.05% | -3.50% |
Apr. 26 | REDCARE PHARMACY : Deutsche Bank reiterates its Buy rating | ZD |
Apr. 26 | REDCARE PHARMACY : Hauck & Aufhauser keeps its Buy rating | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.50% | 2.74B | B | ||
-33.78% | 15.3B | B- | ||
-30.56% | 11.07B | B | ||
+9.74% | 6.13B | C | ||
-9.57% | 5.95B | C+ | ||
+0.88% | 4.79B | D- | ||
+53.60% | 4.36B | - | C | |
-10.49% | 3.69B | B | ||
-12.53% | 3.43B | C- | ||
-6.53% | 3.05B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RDC Stock
- Ratings Redcare Pharmacy NV